10/9/21 ~ VICTORIAN GOVERNMENT PLACES INITIAL ORDERS FOR 1 MILLION RHINOSWABS FOR SARS-CoV-2 TESTING

 Production underway with planning for scaled-up production capacity

 Appointment of distributors in Western Australia and Europe (Benelux)

10 September 2021: Melbourne, Australia. Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in wearable nasal and respiratory technology, has received an initial purchase order for one million Rhinoswabs from the Victorian Department of Health (DH) to support Victoria’s testing capability.

This follows the recent NSW Health Pathology order of one million Rhinoswabs as announced on 11 August....

Maybe this news was leaked yesterday~RNO price rose to 42cps before coming back to 37.5cps

Disc: Hoder in RL

Edit~typo

ETHICS APPROVAL GRANTED FOR CLINICAL TRIAL OF WORLD’S FIRST NASAL SWAB DESIGNED SPECIFICALLY FOR CHILDREN

•  Rhinomed has created the world's first nasal swab designed specifically for children — The Rhinoswab Junior TM
•  Ethics approval has been received for a clinical trial to commence with the Murdoch Children’s Research Institute (MCRI) at The Royal Children’s Hospital in Melbourne
•  Trial seeks to further validate the child-friendly Rhinoswab Junior TM as a safe and effective alternative to current standard of care swabs

27th August 2021: Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in wearable nasal and respiratory technology, has completed development of the world's first nasal swab designed specifically for children. The Rhinoswab Junior has been designed to deliver all the benefits of the existing Rhinoswab but with several novel features that reduce the fear, anxiety and trauma associated with the use of existing standard of care nasal swabs. The company has received Human Research Ethics Committee (HREC) approval to commence a clinical trial of the Rhinoswab Junior at The Royal Children’s Hospital Melbourne....

If they get the right, I'd like to be able use it too! I hate these tests...

DISC: I hold

YEAR ON YEAR GROWTH IN MAJOR MARKETS, COMMERCIALISING NEW NASAL SWAB

TOPLINE

•  Operating revenue for 1H FY21 was A$1.95m up 16.7% (1HFY20 - $1.67m)
•  Loss after income tax for 1H FY21 was A$5.48 (up 3.5%)
•  Total units shipped for 1H FY21 was 145,576
•  Cash reserves of A$5.4m (as at 31 December 2020)
•  Successfully initiated and completed design of a new and novel nasal swab (Rhinoswab) for sampling and use in testing for upper respiratory diseases including SARS-CoV-2, Influenza, etc
•  Clinical validation program completed with the Melbourne based Peter Doherty Institute’s Victorian Infectious Diseases References Library (VIDRL)
•  Rhinoswab registered as a Class 1 device in the USA with the FDA and in Australia with the TGA
•  Commencement of Rhinoswab production program

Disc: I Hold